Assuntos
Erupções Acneiformes/induzido quimicamente , Toxidermias/etiologia , Dermatoses Faciais/induzido quimicamente , Inibidores de Proteínas Quinases/efeitos adversos , Quinazolinas/efeitos adversos , Adenocarcinoma/tratamento farmacológico , Idoso , Cloridrato de Erlotinib , Feminino , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Inibidores de Proteínas Quinases/uso terapêutico , Quinazolinas/uso terapêuticoRESUMO
Se presenta el caso clínico de una paciente joven con cáncer de mama y metástasis óseas en tratamiento con bifosfonatos que acude a consulta de Atención Primaria por dolor maxilar. La paciente fue diagnosticada de osteonecrosis secundaria a bifosfonatos. Se exponen asimismo en el artículo los factores de riesgo, fisiopatología, clínica y tratamiento de esta entidad
The clinical case of a young female patient with bone metastases and breast cancer under treatment with bisphosphonates who was evalued in Primary Care due to jaw pain is presented. Bisphosphonate-associated osteonecrosis was diagnosed. We discuss risk factors, pathophysiology, clinical features and management of the disorder
Assuntos
Humanos , Feminino , Adulto , Difosfonatos/efeitos adversos , Osteonecrose/induzido quimicamente , Maxila/patologia , Neoplasias Ósseas/secundário , Neoplasias da Mama/complicações , Fatores de RiscoRESUMO
The metastatic involvement pattern of breast cancer has been changing in recent years and, in this sense, an increase in the incidence of metastatic involvement of the central nervous system (CNS) is being observed. In this situation, the role that the introduction of new therapeutic agents has must still be defined. In this article, we review the possible role played by treatment with Herceptin in the appearance of metastatic involvements of the CNS.
Assuntos
Anticorpos Monoclonais/efeitos adversos , Antineoplásicos/efeitos adversos , Neoplasias da Mama/patologia , Neoplasias do Sistema Nervoso Central/etiologia , Neoplasias do Sistema Nervoso Central/secundário , Anticorpos Monoclonais Humanizados , Neoplasias do Sistema Nervoso Central/epidemiologia , Feminino , Humanos , TrastuzumabRESUMO
El patrón de afectación metastático del cáncer de mama está cambiando en los últimos años y, en este sentido, se está observando un aumento en la incidencia de afectación metastásica del sistema nervioso central (SNC). En esta situación el papel que puede tener la introducción de nuevos agentes terapéuticos está por definir. En este artículo revisaremos el posible papel que puede desempeñar el tratamiento con Herceptin en la aparición de afectación metastásica del SNC
The metastatic involvement pattern of breast cancer has been changing in recent years and, in this sense, an increase in the incidence of metastatic involvement of the central nervous system (CNS) is being observed. In this situation, the role that the introduction of new therapeutic agents has must still be defined. In this article, we review the possible role played by treatment with Herceptin in the appearance of metastatic involvements of the CNS
